These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27548393)

  • 1. Early
    Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
    Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Nielsen D; Jensen BV; Hendel HW
    J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Johannesen HH; Nielsen D; Schou JV; Jensen BV; Høgdall EV; Hendel HW
    Cancer Med; 2014 Oct; 3(5):1294-301. PubMed ID: 24941936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
    Di Fabio F; Pinto C; Rojas Llimpe FL; Fanti S; Castellucci P; Longobardi C; Mutri V; Funaioli C; Sperandi F; Giaquinta S; Martoni AA
    Gastric Cancer; 2007; 10(4):221-7. PubMed ID: 18095077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
    Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
    Ma B; King AD; Leung L; Wang K; Poon A; Ho WM; Mo F; Chan CML; Chan ATC; Wong SCC
    Ann Oncol; 2017 Jul; 28(7):1576-1581. PubMed ID: 28379285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
    Goshen E; Davidson T; Zwas ST; Aderka D
    Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
    Berger AK; Lücke S; Abel U; Haag GM; Grüllich C; Stange A; Dietrich M; Apostolidis L; Freitag A; Trierweiler C; von Gall C; Ose J; Giesel F; Weber TF; Lordick F; Haberkorn U; Jäger D
    Br J Cancer; 2018 Jul; 119(2):170-175. PubMed ID: 29961759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
    Liu FY; Yen TC; Wang JY; Yang TS
    Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of interim
    Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
    Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
    PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    van Helden EJ; Hoekstra OS; Boellaard R; Roth C; Mulder ER; Verheul HM; Menke-van der Houven van Oordt CW
    PLoS One; 2016; 11(5):e0155178. PubMed ID: 27196139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.